文章：

RhoJ：癌症研究与治疗中的新兴生物标志物和靶点

RhoJ: an emerging biomarker and target in cancer research and treatment

原文发布日期：2024-06-10 

英文摘要：

RhoJ is a Rho GTPase that belongs to the Cdc42 subfamily and has a molecular weight of approximately 21 kDa. It can activate the p21-activated kinase family either directly or indirectly, influencing the activity of various downstream effectors and playing a role in regulating the cytoskeleton, cell movement, and cell cycle. RhoJ’s expression and activity are controlled by multiple upstream factors at different levels, including expression, subcellular localization, and activation. High RhoJ expression is generally associated with a poor prognosis for cancer patients and is mainly due to an increased number of tumor blood vessels and abnormal expression in malignant cells. RhoJ promotes tumor progression through several pathways, particularly in tumor angiogenesis and drug resistance. Clinical data also indicates that high RhoJ expression is closely linked to the pathological features of tumor malignancy. There are various cancer treatment methods that target RhoJ signaling, such as direct binding to inhibit the RhoJ effector pocket, inhibiting RhoJ expression, blocking RhoJ upstream and downstream signals, and indirectly inhibiting RhoJ’s effect. RhoJ is an emerging cancer biomarker and a significant target for future cancer clinical research and drug development. 

摘要翻译：

RhoJ是一种属于Cdc42亚家族的Rho GTP酶，分子量约为21 kDa。它可直接或间接激活p21活化激酶家族，影响多种下游效应器的活性，在细胞骨架调控、细胞运动和细胞周期中发挥作用。RhoJ的表达和活性受多个上游因素在不同层面的调控，包括表达水平、亚细胞定位和活化状态。RhoJ高表达通常与癌症患者不良预后相关，主要源于肿瘤血管数量增加及恶性细胞中的异常表达。RhoJ通过多种途径促进肿瘤进展，尤其在肿瘤血管生成和耐药性方面作用显著。临床数据还表明，RhoJ高表达与肿瘤恶性病理特征密切相关。目前存在多种针对RhoJ信号通路的癌症治疗策略，例如直接结合抑制RhoJ效应器口袋、抑制RhoJ表达、阻断RhoJ上下游信号以及间接抑制RhoJ效应等。RhoJ作为新兴的癌症生物标志物，是未来肿瘤临床研究和药物开发的重要靶点。

原文链接：

RhoJ: an emerging biomarker and target in cancer research and treatment